AUTL
Autolus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Negative Gross Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AUTL
Autolus Therapeutics Plc
A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies
Biological Technology
02/02/2018
06/22/2018
NASDAQ Stock Exchange
647
12-31
Depository Receipts (Ordinary Shares)
The MediaWorks, 191 Wood Lane, London W12 7FP , United Kingdom
--
Autolus Therapeutics plc was incorporated in England and Wales on February 2, 2018. The company is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using the company's extensive suite of proprietary and modular T-cell programming technologies, the company is designing precisely targeted, controlled and highly active T-cell therapies designed to better identify target cells, break down their defense mechanisms, and attack and eliminate these cells.
Earnings Call
Q1/2025
Estimate EPS-0.25
Actual EPS-0.26
Estimate Revenue2.20M
Actual Revenue2.10M
Autolus Therapeutics Q1 2025: Unraveling Key Contradictions in Revenue, Tariffs, and Manufacturing Success
May 19,2025 01:42
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.23
Actual EPS-0.18
Estimate Revenue12.92M
Actual Revenue20.90M
Autolus Therapeutics Q2 2025: Navigating Revenue Recognition, Market Access, and Margin Contradictions
Aug 12,2025 04:46
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.23
Actual EPS-0.3
Estimate Revenue21.31M
Actual Revenue21.19M
Autolus Therapeutics' Q3 2025: Contradictions Emerge on Revenue Recognition, Gross Margins, CMS Coding, and CAR-T Growth
Nov 12,2025 03:26
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AUTL has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.23, missing expectations. The chart below visualizes how AUTL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AUTL has released its 2025 Q3 earnings report, with revenue of 21.19M, reflecting a YoY change of NaN%, and net profit of -79.12M, showing a YoY change of 3.63%. The Sankey diagram below clearly presents AUTL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
